

Appointment of Highly Experienced Business Development and Commercialisation Executive as Non-Executive Director

Memphasys Limited (ASX: MEM), a biotechnology company focused on developing and commercialising innovative products for assisted reproduction and disease diagnosis/prevention, is pleased to announce the appointment of Mr Marjan Mikel as a Non-Executive Director of the Company, effective immediately.

Mr Mikel brings to the Board a strong and diverse track record in business development, commercial leadership, capital markets, and strategic partnership execution across the Medtech, diagnostics, healthcare services, and life sciences sectors. He has held senior executive and board positions in both listed and private companies, with extensive experience in the commercialisation of disruptive technologies and scaling ventures in regulated markets.

He is currently the CEO and Managing Director of Vitasora Health Limited (ASX: VTS), an ASX-listed remote patient monitoring (RPM) company operating in the U.S. healthcare system. Under his leadership, the company has pioneered the commercialisation of a novel respiratory monitoring device and successfully transitioned into a full-service RPM provider. Mr Mikel led capital raises, secured major U.S. ACO and payer contracts, and executed the cross-border acquisition of U.S.-based Orb Health, expanding the company's footprint and capabilities in the U.S. market.

Previously, Mr Mikel founded Healthy Sleep Solutions, building it into Australia's largest sleep health provider before securing ResMed as a strategic investor and leading a successful trade sale to global multinational Air Liquide. He also held senior commercial roles with IMS Health, Merck Sharp & Dohme, Pharmacia, and Searle, with responsibilities across Australia, Asia-Pacific, and Europe.

Importantly, Mr Mikel is familiar with Memphasys and its strategic vision, having previously served as a Non-Executive Director of the Company from June 2018 to March 2020, including as Chair of both the Audit & Risk Committee and the Nomination & Remuneration Committee.

Mr Mikel holds a Master of Commerce from the University of New South Wales, a Graduate Diploma in Education and a Bachelor of Science (Hons) from the University of Sydney and has completed executive studies at the Australian Graduate School of Management. He is also a Member of the Australian Institute of Company Directors (MAICD).

Commenting on the appointment, Memphasys Managing Director and CEO Dr David Ali said: *"We are delighted to welcome Marjan back to the Board of Memphasys. His deep commercial experience, particularly in taking early-stage innovations to market and securing strategic partnerships, aligns strongly with our next phase of growth. His prior involvement with Memphasys, combined with his global perspective and proven ability to execute capital transactions and commercial deals, will be invaluable as*

we drive forward the global expansion of our Felix™ system and accelerate the commercialisation of our RoXsta™ platform.”

This announcement has been authorised for release by the Board of Memphasys Limited.

For further information, please contact:

David Ali
Managing Director – Memphasys Limited
www.memphasys.com.au

Authorised by the Board of Memphasys Limited.

Ends

For further information, please contact:

Dr. David Ali
Managing Director & CEO
Memphasys Limited
Tel: +61 2 8415 7300
E: david.ali@memphasys.com

David Tasker
Managing Director
Chapter One Advisors
Tel: +61 433 112 936
E: dtasker@chapteroneadvisors.com.au

About Memphasys Limited

Memphasys Limited (ASX: MEM) specialises in advanced reproductive biotechnology, developing medical devices, diagnostics, and proprietary media for human and animal applications. With flagship technologies like the Felix™ and RoXsta™ Systems, Memphasys is committed to delivering transformative solutions that enhance fertility outcomes worldwide.

Website: www.memphasys.com